REVERSE-Long COVID-19 With Baricitinib Study

Part of paid clinical trials in San Francisco, California.

Sponsor
Vanderbilt University Medical Center
Study ID
NCT05858515
Phase
PHASE3
Status
Withdrawn

Conditions

  • Post-Acute COVID-19 Syndrome

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Baricitinib 4 MG — DRUG
    Nonproprietary name: Baricitinib
  • Placebo — DRUG
    Placebo

Study Details

REVERSE-LC is a phase 3 trial of baricitinib versus placebo in adults with neurocognitive impairment (a form of Alzheimer's Disease and Related Dementias or ADRD) or cardiopulmonary symptoms due to Long COVID.

Key Dates

Start date
Oct 21, 2024
Status verified
Jan 2025
Primary completion
Dec 31, 2027
Completion
Dec 30, 2029

Study Design

Enrollment
0 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Placebo Comparator: Placebo
    These participants will receive placebo for 24 weeks (6 mo)
  • Experimental: Intervention #1
    These participants will receive baricitinib 4 mg daily for 24 weeks

Primary Outcome Measure

Enrollment [ Time Frame: 6 months ]

Locations (6)

FacilityCityStateZIPSite coordinators
University of California San FranciscoSan FranciscoCalifornia30329-
Yale UniversityNew HavenConnecticut06520-
Emory UniversityAtlantaGeorgia30329-
University of MinnesotaMinneapolisMinnesota55455-
Vanderbilt UniversityNashvilleTennessee37203-
Vanderbilt University Medical CenterNashvilleTennessee37232-8300-

Find similar trials in San Francisco, CA

By research site
University of California San Francisco· San Francisco, CAYale University· New Haven, CTEmory University· Atlanta, GAUniversity of Minnesota· Minneapolis, MNVanderbilt University· Nashville, TNVanderbilt University Medical Center· Nashville, TN

Related Studies